Angion is currently testing ANG-3777 in Phase 2 and Phase 3 clinical trials in patients with acute kidney injury resulting from kidney transplantation and from cardiac surgery. Improvement in kidney function is one of several key endpoints.
ANG-3777 is engineered to mimic the biological activity of HGF in order to address the timing mismatch of HGF levels and c-MET availability, which may activate this important repair pathway subsequently promoting tissue repair and possible improved organ function.
ANG-3777 is an investigational product and not approved by the FDA.
A randomized Phase 2 trial of 28 patients receiving a kidney transplant and experiencing signs and symptoms of delayed graft function has been completed and the data presented at American Society of Nephrology 2019.
A randomized, double-blind, placebo-controlled Phase 3 trial examining the efficacy of ANG-3777 in reducing the severity of delayed graft function in 220 patients after kidney transplantation is currently enrolling. Data is expected in 2020.
A randomized, double-blind, placebo-controlled Phase 2 trial examining the efficacy of ANG-3777 in reducing acute kidney injury in 240 patients after a cardiac procedure is currently enrolling. Data are expected in 2020.
Angion’s robust pipeline includes ANG-3070, an oral small molecule in development as a potential treatment for fibrosis and other severe organ damage.
ANG-3070 is an orally bioavailable small molecule soon to begin a Phase 1 healthy volunteer trial and could be evaluated in a variety of fibrosis-related diseases, such as idiopathic pulmonary fibrosis and focal segmental glomerulosclerosis.